Efficacy and safety of odevixibat in patients with Alagille syndrome (ASSERT): a phase 3, double-blind, randomised, placebo-controlled trial

Nadia Ovchinsky, Madeleine Aumar, Alastair Baker, Ulrich Baumann, Philip Bufler, Mara Cananzi, Piotr Czubkowski, Özlem Durmaz, Ryan Fischer, Giuseppe Indolfi, Wikrom W Karnsakul, Florence Lacaille, Way S Lee, Giuseppe Maggiore, Philip Rosenthal, Mathias Ruiz, Etienne Sokal, Ekkehard Sturm, Wendy van der Woerd, Henkjan J Verkade, Andrew Wehrman, Christine Clemson, Qifeng Yu, Quanhong Ni, Jessica Ruvido, Susan Manganaro, Jan P Mattsson

Open source

DOI: 10.1016/s2468-1253(24)00074-8
Published: 2024-07
Container: The Lancet Gastroenterology & Hepatology
Publisher: Elsevier BV
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/s2468-1253-24-00074-8,
  title = {Efficacy and safety of odevixibat in patients with Alagille syndrome (ASSERT): a phase 3, double-blind, randomised, placebo-controlled trial},
  author = {Nadia Ovchinsky and Madeleine Aumar and Alastair Baker and Ulrich Baumann and Philip Bufler and Mara Cananzi and Piotr Czubkowski and Özlem Durmaz and Ryan Fischer and Giuseppe Indolfi and Wikrom W Karnsakul and Florence Lacaille and Way S Lee and Giuseppe Maggiore and Philip Rosenthal and Mathias Ruiz and Etienne Sokal and Ekkehard Sturm and Wendy van der Woerd and Henkjan J Verkade and Andrew Wehrman and Christine Clemson and Qifeng Yu and Quanhong Ni and Jessica Ruvido and Susan Manganaro and Jan P Mattsson},
  year = {2024},
  journal = {The Lancet Gastroenterology \&amp; Hepatology},
  doi = {10.1016/s2468-1253(24)00074-8},
  url = {https://doi.org/10.1016/s2468-1253(24)00074-8}
}

RIS

TY  - JOUR
TI  - Efficacy and safety of odevixibat in patients with Alagille syndrome (ASSERT): a phase 3, double-blind, randomised, placebo-controlled trial
AU  - Nadia Ovchinsky
AU  - Madeleine Aumar
AU  - Alastair Baker
AU  - Ulrich Baumann
AU  - Philip Bufler
AU  - Mara Cananzi
AU  - Piotr Czubkowski
AU  - Özlem Durmaz
AU  - Ryan Fischer
AU  - Giuseppe Indolfi
AU  - Wikrom W Karnsakul
AU  - Florence Lacaille
AU  - Way S Lee
AU  - Giuseppe Maggiore
AU  - Philip Rosenthal
AU  - Mathias Ruiz
AU  - Etienne Sokal
AU  - Ekkehard Sturm
AU  - Wendy van der Woerd
AU  - Henkjan J Verkade
AU  - Andrew Wehrman
AU  - Christine Clemson
AU  - Qifeng Yu
AU  - Quanhong Ni
AU  - Jessica Ruvido
AU  - Susan Manganaro
AU  - Jan P Mattsson
PY  - 2024
JO  - The Lancet Gastroenterology &amp; Hepatology
DO  - 10.1016/s2468-1253(24)00074-8
UR  - https://doi.org/10.1016/s2468-1253(24)00074-8
ER  -

APA

Ovchinsky, N., Aumar, M., Baker, A., Baumann, U., Bufler, P., Cananzi, M., Czubkowski, P., Durmaz, Ö., Fischer, R., Indolfi, G., Karnsakul, W. W., Lacaille, F., Lee, W. S., Maggiore, G., Rosenthal, P., Ruiz, M., Sokal, E., Sturm, E., Woerd, W. V. D., Verkade, H. J., Wehrman, A., Clemson, C., Yu, Q., Ni, Q., Ruvido, J., Manganaro, S., & Mattsson, J. P. (2024). Efficacy and safety of odevixibat in patients with Alagille syndrome (ASSERT): a phase 3, double-blind, randomised, placebo-controlled trial. The Lancet Gastroenterology & Hepatology. https://doi.org/10.1016/s2468-1253(24)00074-8

Source records

crossref · retrieved 2026-09-26T15:58:40.482Z